Timetable

Thursday, October 1st
16:55-17:25	Composite endpoints and PROs in cGvHD: are we measuring what matters? Industry-Supported Meet the Expert Session by Therakos
17:25-17:30	Break
17:30-18:00	When Is a Blip Just a Blip? Industry-Supported Meet the Expert Session by MSD
18:00-18:05	Break
18:05-18:35	Beyond Response: Can Third-Generation CD19 CAR-T Deliver Durable Disease Control in r/r NHL and B-ALL? Updated SUMM1T Results Industry-Supported “Special Lecture” by MicroCRISPR
18:35	Welcome Reception

Friday, October 2nd
08:00-08:10	“Good morning” Coffee
08:10-08:15	Welcome Note by Congress Co-Chairs
08:15-09:45	Session 1: AML and graft manipulation
09:45-10:00	Coffee Break, Poster Viewing and Visit Exhibition
10:00-11:30	Lectin pathway inhibition as frontline therapy in TA-TMA: the good choice Industry-Supported Symposium by Omeros
11:30-11:40	Short Break
11:40-13:10	Session 2: CAR T in NHL
13:10-13:45	Lunch Break, Poster Viewing and Visit Exhibition
13:45-14:45	*Controversy in FLT3-ITD AML: Is the Optimal Duration of Maintenance Therapy Clearly Defined?* Industry-Supported Symposium by Daiichi Sankyo
14:45-15:00	Short Break
15:00-16:30	Session 3: PTCy and clinical endpoints
16:30-17:00	Coffee Break, Poster Viewing and Visit Exhibition
17:00-18:30	Session 4: Multiple myeloma
19:30	Networking Event

Saturday, October 3rd
08:30-10:00	Session 5: ALL
10:00-10:20	Coffee Break, Poster Viewing and Visit Exhibition
10:20-11:30	Session 6: PTLD
11:30-13:00	Session 7: Donor selection and GVHD prophylaxis
13:00-13:30	Lunch Break, Poster Viewing and Visit Exhibition
13:30-15:00	Controversy: cGVHD management: sufficient evidence to standardize or too complex to simplify? Industry-Supported Symposium by Sanofi
15:00-15:10	Short Break
15:10-16:40	Session 8: MRD
16:40-17:00	Coffee Break, Poster Viewing and Visit Exhibition
17:00-18:30	Session 9: Hemoglobinopathy and aplastic anemia
18:30	Poster Walk and Awards Session (Poster Area)